DK2363414T3 - Stedstyret modifikation af FVIII - Google Patents

Stedstyret modifikation af FVIII Download PDF

Info

Publication number
DK2363414T3
DK2363414T3 DK11153300.6T DK11153300T DK2363414T3 DK 2363414 T3 DK2363414 T3 DK 2363414T3 DK 11153300 T DK11153300 T DK 11153300T DK 2363414 T3 DK2363414 T3 DK 2363414T3
Authority
DK
Denmark
Prior art keywords
fviii
site
directed modification
modification
directed
Prior art date
Application number
DK11153300.6T
Other languages
Danish (da)
English (en)
Inventor
Clark Q Pan
John E Murphy
Jonathan S Strauss
Hendri Tjandra
Jianmin Chen
Thomas Barnett
Deqian Wamg
Baisong Mei
Liang Tang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2363414(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Application granted granted Critical
Publication of DK2363414T3 publication Critical patent/DK2363414T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
DK11153300.6T 2004-11-12 2005-11-14 Stedstyret modifikation af FVIII DK2363414T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12
EP05849392.5A EP1824988B1 (en) 2004-11-12 2005-11-14 Site-directed modification of fviii

Publications (1)

Publication Number Publication Date
DK2363414T3 true DK2363414T3 (da) 2022-08-08

Family

ID=36337298

Family Applications (3)

Application Number Title Priority Date Filing Date
DK11153300.6T DK2363414T3 (da) 2004-11-12 2005-11-14 Stedstyret modifikation af FVIII
DK11153297.4T DK2371856T3 (en) 2004-11-12 2005-11-14 Site-directed modifikation af FVIII
DK05849392.5T DK1824988T3 (en) 2004-11-12 2005-11-14 LOCATION-SPECIFIC MODIFICATION OF FVIII

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK11153297.4T DK2371856T3 (en) 2004-11-12 2005-11-14 Site-directed modifikation af FVIII
DK05849392.5T DK1824988T3 (en) 2004-11-12 2005-11-14 LOCATION-SPECIFIC MODIFICATION OF FVIII

Country Status (32)

Country Link
US (4) US7632921B2 (enExample)
EP (9) EP3130601B1 (enExample)
JP (5) JP2008524117A (enExample)
KR (7) KR20180110192A (enExample)
CN (6) CN105753968A (enExample)
AU (1) AU2005304622B2 (enExample)
BE (1) BE2019C523I2 (enExample)
BR (2) BRPI0517795B8 (enExample)
CA (1) CA2586379C (enExample)
CY (3) CY1119292T1 (enExample)
DK (3) DK2363414T3 (enExample)
ES (4) ES2633916T3 (enExample)
FR (1) FR19C1031I2 (enExample)
HN (1) HN2007015683A (enExample)
HR (2) HRP20180481B1 (enExample)
HU (5) HUE033776T2 (enExample)
IL (3) IL182903A (enExample)
LT (5) LT2363414T (enExample)
LU (1) LUC00118I2 (enExample)
MA (1) MA29663B1 (enExample)
MX (3) MX350293B (enExample)
NL (1) NL300989I2 (enExample)
NO (3) NO345800B1 (enExample)
NZ (1) NZ555032A (enExample)
PH (2) PH12014500352B1 (enExample)
PL (3) PL1824988T3 (enExample)
PT (4) PT1824988T (enExample)
RU (1) RU2423380C2 (enExample)
SI (4) SI2363414T1 (enExample)
UA (1) UA95225C2 (enExample)
WO (1) WO2006053299A2 (enExample)
ZA (1) ZA200703696B (enExample)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
MXPA06015234A (es) * 2004-06-30 2007-11-22 Nektar Therapeutics Al Corp Conjugados de fraccion polimero-factor ix.
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
JP2008524117A (ja) 2004-11-12 2008-07-10 バイエル・ヘルスケア・エルエルシー Ｆｖｉｉｉの特定部位の変更
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CA2653154A1 (en) * 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Prolonged fix analogues and derivatives
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
ES2521490T3 (es) 2006-12-15 2014-11-12 Baxter International Inc. Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada.
AU2008237411B2 (en) 2007-04-03 2013-10-03 Ratiopharm Gmbh Methods of treatment using glycopegylated G-CSF
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
JP2011503101A (ja) * 2007-11-09 2011-01-27 バクスター・インターナショナル・インコーポレイテッド 修飾された組換え第ｖｉｉｉ因子およびフォンウィルブランド因子ならびにその使用方法
EP2626079A3 (en) * 2008-02-27 2014-03-05 Novo Nordisk A/S Conjungated factor VIII molecules
KR20110022604A (ko) 2008-05-16 2011-03-07 바이엘 헬스케어 엘엘씨 표적화 응고 인자 및 그의 사용 방법
US20110286988A1 (en) * 2008-06-04 2011-11-24 Bayer Healthcare Llc FVIII Muteins for Treatment of Von Willebrand Disease
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
SMT201800486T1 (it) * 2008-10-17 2018-11-09 Baxalta Inc Fattori sanguigni modificati comprendenti un grado basso di polimero solubile in acqua
KR20110093775A (ko) * 2008-11-03 2011-08-18 바이엘 헬스케어 엘엘씨 혈우병 치료 방법
WO2010060081A1 (en) * 2008-11-24 2010-05-27 Bayer Healthcare Llc Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
CA2748662A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
KR101544245B1 (ko) 2009-02-03 2015-08-12 아뮤닉스 오퍼레이팅 인코포레이티드 연장된 재조합 폴리펩티드 및 이를 포함하는 조성물
WO2010102886A1 (en) * 2009-02-19 2010-09-16 Novo Nordisk A/S Modification of factor viii
JP5759976B2 (ja) * 2009-03-20 2015-08-05 ハンミ・サイエンス・カンパニー・リミテッド 位置特異的な生理活性ポリペプチド結合体の調製方法
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
PT2459224T (pt) 2009-07-27 2016-09-05 Baxalta Inc Conjugados proteicos para coagulação sanguínea
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
AU2010277438B2 (en) 2009-07-27 2015-08-20 Baxalta GmbH Glycopolysialylation of non-blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG178141A1 (en) 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
JP5813641B2 (ja) 2009-08-24 2015-11-17 アムニクス オペレーティング インコーポレイテッド 凝固第ｉｘ因子組成物ならびにそれを製造および使用する方法
EA025416B1 (ru) 2009-12-06 2016-12-30 Байоджен Хемофилия Инк. Способ предотвращения или лечения эпизодов кровотечений с использованием химерного полипептида фактора viii длительного действия
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
CN102770449B (zh) 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
PH12012501664A1 (en) * 2010-02-21 2012-10-22 Bayer Healthcare Llc Method for activation and conjugation of biomolecules
DK3549963T3 (da) 2010-04-15 2022-02-14 Kodiak Sciences Inc Zwitterionholdige polymerer med høj molekylvægt
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
WO2012006623A1 (en) * 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
MX351220B (es) * 2010-11-05 2017-10-05 Baxalta GmbH Una variante nueva del factor viii antihemofilico que tiene actividad especifica incrementada.
CA2821945A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Aqueous factor viii solution
WO2012087838A1 (en) 2010-12-22 2012-06-28 Baxter International Inc. Materials and methods for conjugating a water soluble fatty acid derivative to a protein
EP3808378A1 (en) * 2011-05-27 2021-04-21 Baxalta GmbH Therapeutic proteins with increased half-life and methods of preparing same
DK2717898T3 (en) 2011-06-10 2019-03-25 Bioverativ Therapeutics Inc COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF
HK1199889A1 (en) 2011-07-01 2015-07-24 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
PT2729161T (pt) 2011-07-08 2019-04-01 Bioverativ Therapeutics Inc Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
AR088161A1 (es) 2011-09-23 2014-05-14 Novo Nordisk As Analogos de glucagon
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
DK2814502T3 (en) 2012-02-15 2017-12-18 Csl Behring Gmbh Von Willebrand Factor variants with improved Factor VIII binding affinity
SI2822577T1 (sl) * 2012-02-15 2019-07-31 Bioverativ Therapeutics Inc. Rekombinantni proteini faktorja VIII
EP3564260B1 (en) 2012-02-15 2022-10-19 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
AU2013270682A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Procoagulant compounds
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3446700A1 (en) 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
SG11201507618YA (en) * 2013-03-15 2015-10-29 Bayer Healthcare Llc Recombinant factor viii formulations
SG10201805207QA (en) 2013-03-15 2018-07-30 Bioverativ Therapeutics Inc Factor viii polypeptide formulations
SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations
MX362275B (es) 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
EP3033098B1 (en) 2013-08-14 2022-06-22 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
SI3041513T1 (sl) 2013-09-08 2020-11-30 Kodiak Sciences Inc. Zwitterionski polimerni konjugati faktorja VIII
MX2016005333A (es) * 2013-10-22 2017-02-15 Dbv Tech Método para tratar la hemofilia induciendo tolerancia a factores sanguíneos.
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
EP4332839A3 (en) 2013-12-06 2024-06-05 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EP3097118B1 (en) 2014-01-20 2018-07-18 Octapharma AG A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
US20160347787A1 (en) 2014-02-04 2016-12-01 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2015132724A1 (en) * 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
WO2015148444A1 (en) 2014-03-24 2015-10-01 Biogen Ma Inc. Lyophilized factor ix formulations
US11181534B2 (en) * 2014-04-04 2021-11-23 Bloodworks Routine laboratory and point-of-care (POC) testing for hemostasis
AU2015243961A1 (en) 2014-04-10 2016-10-27 Bayer Healthcare Llc Compounded media powder formulation and method of preparation of liquid medium for cell culture
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
ES2844232T3 (es) 2014-07-02 2021-07-21 CSL Behring Lengnau AG Factor de Von Willebrand modificado
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
SG10201910900WA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
MX2017014503A (es) 2015-05-22 2018-08-01 CSL Behring Lengnau AG Polipeptidos de factor de von willebrand truncado para tratar hemofilia.
JP6909203B2 (ja) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
JP6851381B6 (ja) 2016-01-07 2021-04-21 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 変異切断型フォンウィルブランド因子
DK3400238T3 (da) 2016-01-07 2021-07-26 CSL Behring Lengnau AG Muteret von willebrand faktor
US20230151078A1 (en) * 2016-06-24 2023-05-18 Mogam Instiitute For Biomedical Research Recombinant single-chain fviii and chemical conjugate thereof
SG10201912360SA (en) 2016-11-11 2020-02-27 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
KR20190073576A (ko) 2016-11-11 2019-06-26 체에스엘 베링 렝나우 아게 혈액 응고 장애의 치료 또는 예방에서 혈관외 투여를 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
JP2020504084A (ja) 2016-11-16 2020-02-06 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 赤血球標的化第ｖｉｉｉ因子およびその使用方法
AU2017366709A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
JP2019536794A (ja) 2016-12-02 2019-12-19 バイオベラティブ セラピューティクス インコーポレイテッド 凝固因子に対する免疫寛容を誘導する方法
EA201991768A1 (ru) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. Слитые белки на основе фактора ix и способы их получения и пути применения
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
BR112020023168A2 (pt) 2018-05-18 2021-02-09 Zhengzhou Gensciences Inc. proteína de fusão de fviii aprimorada e uso da mesma
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021091881A1 (en) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
CN114828870A (zh) * 2019-12-06 2022-07-29 费城儿童医院 用于调节因子viii功能的组合物和方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
WO1994007510A1 (en) 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
AU6029594A (en) * 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
EP0730660A4 (en) 1993-10-29 1998-02-25 Incyte Pharma Inc CHIMEAN PROTEINE PROTEASE NEXIN-1 CONTAINING VARIANTS
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
WO1997001197A1 (en) * 1995-06-21 1997-01-09 Motorola Inc. Method and antenna for providing an omnidirectional pattern
WO1997003195A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
JP4410852B2 (ja) * 1996-08-02 2010-02-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 単一の共有結合ｎ末端水溶性ポリマーを有するポリペプチド
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
CA2296770A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CN1113656C (zh) * 1997-10-17 2003-07-09 丰收技术股份有限公司 从富含血小板的血浆中沉淀富集生长因子的纤维蛋白原浓缩物
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
BR9909978A (pt) 1998-04-27 2000-12-26 Opperbas Holding Bv Composição farmacêutica para administração parenteral, processo para tratamento de um paciente sofrendo de hemofilia, e, uso de uma partìcula coloidal
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP1129186B2 (de) 1998-11-10 2016-11-30 Stichting Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
EP1183354A2 (en) 1999-05-24 2002-03-06 The American National Red Cross Methods of reducing factor viii clearance and compositions therefor
CA2739933A1 (en) * 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
MXPA03002256A (es) 2000-09-19 2003-09-10 Univ Emory Factor viii modificado.
JP2005518181A (ja) 2001-01-12 2005-06-23 ジ・アメリカン・ナショナル・レッド・クロス 第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物
IL157842A0 (en) * 2001-03-22 2004-03-28 Novo Nordisk Healthcare Ag Coagulation factor vii derivatives
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
AU2002312660A1 (en) 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
CA2450732A1 (en) 2001-06-14 2002-12-27 John H. Griffin Stabilized proteins with engineered disulfide bonds
EP1572889B1 (en) 2001-10-05 2008-12-17 Expression Therapeutics, LLC Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
CN1646564A (zh) 2002-04-18 2005-07-27 默克专利有限公司 修饰的因子ⅷ
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
ATE399185T1 (de) 2002-12-31 2008-07-15 Nektar Therapeutics Al Corp Maleinsäureamid polymerderivate und ihre biokonjugate
CN100343304C (zh) 2002-12-31 2007-10-17 尼克塔治疗亚拉巴马公司 水解稳定的马来酰亚胺封端的聚合物
CA2509939C (en) 2003-01-06 2013-05-21 Nektar Therapeutics Al, Corporation Thiol-selective water-soluble polymer derivatives
EP2572732A1 (en) 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
CA2525464A1 (en) * 2003-05-12 2004-11-25 Qun Yin Novel poly(ethylene glycol) modified compounds and uses thereof
US7887789B2 (en) 2003-05-23 2011-02-15 Nektar Therapeutics Polymer derivatives having particular atom arrangements
EP1502921A1 (en) 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
EP1682106A4 (en) 2003-10-30 2008-06-11 Univ Emory MODIFIED FVIII WITH REDUCED IMMUNOGENICITY BY MUTAGENESIS OF A2 AND C2 EPITOPES
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP1699469B1 (en) 2003-12-03 2010-04-07 University of Rochester Recombinant factor viii having increased specific activity
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
JP2008524117A (ja) 2004-11-12 2008-07-10 バイエル・ヘルスケア・エルエルシー Ｆｖｉｉｉの特定部位の変更
US20080227691A1 (en) 2005-04-01 2008-09-18 Novo Nordisk Health Care Ag Blood Coagulation FVIII Analogues
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates

Also Published As

Publication number Publication date
JP6487895B2 (ja) 2019-03-20
CN105753968A (zh) 2016-07-13
DK2371856T3 (en) 2022-08-08
HUE033776T2 (en) 2018-01-29
NL300989I1 (nl) 2019-05-22
JP6559642B2 (ja) 2019-08-14
HK1182121A1 (en) 2013-11-22
DK1824988T3 (en) 2017-08-07
IL232540A0 (en) 2014-06-30
CN105148287B (zh) 2019-07-09
NO20072997L (no) 2007-06-27
BR122016022033B1 (pt) 2021-03-02
CN103102406A (zh) 2013-05-15
SI1824988T1 (sl) 2017-11-30
AU2005304622B2 (en) 2012-03-29
US9364520B2 (en) 2016-06-14
PT1824988T (pt) 2017-07-21
KR20140091618A (ko) 2014-07-21
PH12014500352B1 (en) 2019-09-25
JP2008524117A (ja) 2008-07-10
PL2371856T3 (pl) 2022-08-22
EP3243833B1 (en) 2020-06-17
KR101654011B1 (ko) 2016-09-05
US20060115876A1 (en) 2006-06-01
PH12019501613A1 (en) 2020-09-14
LT2371856T (lt) 2022-08-25
JP2017105773A (ja) 2017-06-15
JP6018238B2 (ja) 2016-11-02
IL234433B (en) 2019-11-28
KR20160105928A (ko) 2016-09-07
EP2363414B1 (en) 2022-05-18
LT1824988T (lt) 2017-10-25
KR20180110192A (ko) 2018-10-08
US20100081615A1 (en) 2010-04-01
MX350293B (es) 2017-09-04
MA29663B1 (fr) 2008-08-01
FR19C1031I2 (fr) 2020-06-05
HUE059193T2 (hu) 2022-10-28
HUS1900026I1 (hu) 2022-04-28
NZ555032A (en) 2010-02-26
JP2013067621A (ja) 2013-04-18
NO20210454A1 (no) 2007-06-27
PL2363414T3 (pl) 2022-09-05
RU2007121517A (ru) 2008-12-20
BRPI0517795A (pt) 2008-10-21
HK1218718A1 (zh) 2017-03-10
PT3130601T (pt) 2020-10-01
CN103214569A (zh) 2013-07-24
KR101243564B1 (ko) 2013-03-27
PH12014500352A1 (en) 2015-07-20
KR20070110260A (ko) 2007-11-16
LT2363414T (lt) 2022-10-25
CY2019024I2 (el) 2019-11-27
JP2017101028A (ja) 2017-06-08
EP1824988B1 (en) 2017-04-19
EP3153181A1 (en) 2017-04-12
ES2821832T3 (es) 2021-04-27
HK1117875A1 (en) 2009-01-23
EP3130601B1 (en) 2020-07-15
CY1123384T1 (el) 2021-12-31
HN2007015683A (es) 2011-07-11
LUC00118I2 (enExample) 2019-12-27
CN101124331B (zh) 2013-04-24
CN103214569B (zh) 2016-12-28
LTC1824988I2 (lt) 2021-02-25
KR101468345B1 (ko) 2014-12-03
NO20200044A1 (no) 2007-06-27
PT2363414T (pt) 2022-08-04
BRPI0517795B8 (pt) 2021-05-25
CY1119292T1 (el) 2018-02-14
EP2363414A3 (en) 2012-03-21
NO345800B1 (no) 2021-08-09
EP3243833A1 (en) 2017-11-15
CN103102406B (zh) 2015-05-27
HRP20180481B1 (hr) 2022-02-18
CN107082806A (zh) 2017-08-22
WO2006053299A2 (en) 2006-05-18
SI3130601T1 (sl) 2020-11-30
LT3130601T (lt) 2020-09-10
WO2006053299A3 (en) 2006-08-24
HRP20070268B1 (hr) 2018-04-20
UA95225C2 (ru) 2011-07-25
KR20120136413A (ko) 2012-12-18
MX2007005466A (es) 2007-10-19
JP2015134780A (ja) 2015-07-27
CA2586379C (en) 2012-04-03
ES2633916T3 (es) 2017-09-26
KR20130036780A (ko) 2013-04-12
KR101904630B1 (ko) 2018-10-04
HUE050542T2 (hu) 2020-12-28
BE2019C523I2 (enExample) 2025-02-10
EP1824988A2 (en) 2007-08-29
IL182903A0 (en) 2007-08-19
HRP20070268A2 (en) 2007-09-30
EP3323829B1 (en) 2020-07-15
US20130274445A1 (en) 2013-10-17
EP2371856B1 (en) 2022-05-18
PT2371856T (pt) 2022-08-12
BRPI0517795B1 (pt) 2020-03-31
EP2363414A2 (en) 2011-09-07
EP2371856A2 (en) 2011-10-05
ES2930143T3 (es) 2022-12-07
HRP20180481A2 (hr) 2018-06-29
EP2772500A1 (en) 2014-09-03
EP3323829A1 (en) 2018-05-23
NO344606B1 (no) 2020-02-10
CN105148287A (zh) 2015-12-16
EP3130601A1 (en) 2017-02-15
NL300989I2 (nl) 2019-11-28
IL182903A (en) 2014-09-30
LUC00118I1 (enExample) 2019-05-13
US9096656B2 (en) 2015-08-04
EP3243834A1 (en) 2017-11-15
FR19C1031I1 (enExample) 2019-06-28
HUE060016T2 (hu) 2023-01-28
SI2363414T1 (sl) 2022-09-30
EP2772500B1 (en) 2019-12-25
EP2371856A3 (en) 2012-03-14
US7632921B2 (en) 2009-12-15
CY2019024I1 (el) 2019-11-27
ZA200703696B (en) 2008-08-27
IL232540A (en) 2017-08-31
KR101483917B1 (ko) 2015-01-16
PL1824988T3 (pl) 2018-01-31
KR20140019489A (ko) 2014-02-14
US20160051633A1 (en) 2016-02-25
BRPI0517795A8 (pt) 2018-12-26
ES2930159T3 (es) 2022-12-07
SI2371856T1 (sl) 2022-09-30
AU2005304622A1 (en) 2006-05-18
LTPA2019509I1 (lt) 2019-08-26
JP6109523B2 (ja) 2017-04-05
CN101124331A (zh) 2008-02-13
MX392760B (es) 2025-03-24
BR122016022033B8 (pt) 2021-05-25
EP1824988A4 (en) 2008-12-31
CA2586379A1 (en) 2006-05-18
RU2423380C2 (ru) 2011-07-10

Similar Documents

Publication Publication Date Title
DK2363414T3 (da) Stedstyret modifikation af FVIII
DK1802579T3 (da) Derivater af 3-arylaminopyridin
DK1992697T3 (da) Fremstilling af TNFR-Fc
DK1778618T3 (da) Syntese af triethylentetraminer
DE602005012267D1 (de) N von geräten
DK2377869T3 (da) Syntese af Bortezomib
DK1720866T3 (da) Fremgangsmåde
DK1745062T3 (da) Forbedrede modulatorer af koagulationsfaktorer
DE602005013349D1 (de) Optisches siliziumbauelement
DK1587542T3 (da) Anvendelse af anti-CD100-antistoffer
DK1940465T3 (da) Ny anvendelse af anti-IL-1beta-antistoffer
NO20043305D0 (no) Preparation of lodixanol
DK1763520T3 (da) Anvendelse af trisubstituerede benzopyranoner
FI20040603A0 (fi) Lastenistuin
DK2301576T3 (da) Terapeutisk anvendelse af anti-CS1-antistoffer
FR2877833B1 (fr) Correcteur de lordoses
DK1730109T3 (da) Syntese af pyrrol-2-carbonitriler
AT6947U3 (de) Bob
FI20041183L (fi) Integroitu linssi
AT7051U3 (de) Bob
DK1787450T3 (da) Udvælgelse af information
DK1968641T3 (da) Fremstilling af konjugater
ITMI20041764A1 (it) Indumento multifunzionale
FI20040602A0 (fi) Lastenistuin
UA11866S (uk) Комплект спецодягу